tetano
Editor, Senior Moderator
Front Immunol
. 2021 Sep 30;12:762006.
doi: 10.3389/fimmu.2021.762006. eCollection 2021.
Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination
Samy Hakroush[SUP] 1 [/SUP], Björn Tampe[SUP] 2 [/SUP]
Affiliations
Abstract
As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for COVID-19 vaccines to control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge with regard to adverse events of COVID-19 vaccines during post-marketing surveillance. Interestingly, four cases of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) presenting with pauci-immune crescentic glomerulonephritis (GN) after COVID-19 mRNA vaccination have already been reported. We here expand our current knowledge of this rare but important association and report a case of AAV presenting with massive rhabdomyolysis and pauci-immune crescentic GN after Pfizer-BioNTech COVID-19 mRNA vaccination. As huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must continue to assess vaccine safety important for the detection of any events associated with COVID-19 vaccination. This is especially relevant in complex diseases where diagnosis is often challenging, as in our patient with AAV presenting with massive rhabdomyolysis and pauci-immune crescentic GN.
Keywords: ANCA-associated vasculitis (AAV); acute kidney injury (AKI); anti-neutrophil cytoplasmic antibody (ANCA); coronavirus disease 2019 (COVID-19); pauci-immune crescentic glomerulonephritis (GN); rhabdomyolysis; vaccination.
. 2021 Sep 30;12:762006.
doi: 10.3389/fimmu.2021.762006. eCollection 2021.
Case Report: ANCA-Associated Vasculitis Presenting With Rhabdomyolysis and Pauci-Immune Crescentic Glomerulonephritis After Pfizer-BioNTech COVID-19 mRNA Vaccination
Samy Hakroush[SUP] 1 [/SUP], Björn Tampe[SUP] 2 [/SUP]
Affiliations
- PMID: 34659268
- PMCID: PMC8514980
- DOI: 10.3389/fimmu.2021.762006
Abstract
As the coronavirus disease 2019 (COVID-19) pandemic is ongoing and new variants of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are emerging, there is an urgent need for COVID-19 vaccines to control disease outbreaks by herd immunity. Surveillance of rare safety issues related to these vaccines is progressing, since more granular data emerge with regard to adverse events of COVID-19 vaccines during post-marketing surveillance. Interestingly, four cases of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) presenting with pauci-immune crescentic glomerulonephritis (GN) after COVID-19 mRNA vaccination have already been reported. We here expand our current knowledge of this rare but important association and report a case of AAV presenting with massive rhabdomyolysis and pauci-immune crescentic GN after Pfizer-BioNTech COVID-19 mRNA vaccination. As huge vaccination programs are ongoing worldwide, post-marketing surveillance systems must continue to assess vaccine safety important for the detection of any events associated with COVID-19 vaccination. This is especially relevant in complex diseases where diagnosis is often challenging, as in our patient with AAV presenting with massive rhabdomyolysis and pauci-immune crescentic GN.
Keywords: ANCA-associated vasculitis (AAV); acute kidney injury (AKI); anti-neutrophil cytoplasmic antibody (ANCA); coronavirus disease 2019 (COVID-19); pauci-immune crescentic glomerulonephritis (GN); rhabdomyolysis; vaccination.